over the counter

#fivemin-widget-blogsmith-image-566507{display:none;} .cke_show_borders #fivemin-widget-blogsmith-image-566507, #postcontentcontainer #fivemin-widget-blogsmith-image-566507{width:620px;height:439px;display:block;}With a cold coming on, you're summoning all your energy just to venture out to the...

Johnson & Johnson's troubled McNeil subsidiary announced a recall of more than 13 million packages of Rolaids because of consumer reports of metal and wood particles in the products. McNeil Consumer Healthcare, which makes non-prescription drugs such as Tylenol and Benadryl, said it was...

CVS has agreed to pay Pennsylvania $250,000 to settle consumer complaints that it sold expired food and over-the-counter drugs. The chain must also give $2 coupons to any consumer finding out-of-date merchandise on store shelves. The settlement announced today by state Attorney General Tom Corbett...

Johnson & Johnson's earnings for the second quarter of 2010 rose 5.4% to $3.4 billion, or $1.23 per share, from $3.2 billion or $1.15 per share, the company announced Tuesday morning. Adjusted earnings, which exclude litigation costs, were $1.21 per share.

Johnson & Johnson's McNeil Consumer Healthcare has added five lots of its popular over-the-counter drugs, Benadryl and Tylenol, to its recall list and is offering consumers refunds or product coupons. The company says in a statement that the lots were "inadvertently omitted from the initial...

Earlier this week, Walgreens announced with great fanfare that it was selling a controversial over-the-counter genetics test. The drug store chain quickly changed its mind after the Food and Drug Administration objected, ending the bewildering episode as quickly as it started. Testing your own DNA...

Sanofi-Aventis announced Monday it will acquire Chattem Inc. for about $1.9 billion -- paying $93.50 per share, a 34% premium over Chattem's closing price Friday. The deal will create the world's fifth-largest consumer health-care company by revenues and helps Sanofi diversify into over-the-counter and consumer brands: a strategy used by Johnson & Johnson, and one many pharmas seek to adopt before the coming patent cliff.

If President Obama wants to end the kind of complex trading that nearly brought the U.S. financial system to its knees, a more robust plan is needed to control them than the one his administration has put forth, the nation's top securities regulator told Congress on Tuesday. A White House plan to...